OK-101 Phase 2 Dry Eye Data Presentation at ARVO Partner Symposium

OKYO Pharma, a biopharmaceutical firm listed on NASDAQ, is set to present data from its Phase 2 clinical trial of OK-101, a promising treatment for inflammatory dry eye disease (DED), at the Dry Horizons Symposium. Scheduled for May 3, 2024, in Seattle, the event will feature a presentation by Gary Jacob, the company's CEO, from 2:50 to 3:45 PM PDT at the Four Seasons Hotel.

The Dry Horizons Symposium is a gathering of clinical experts and industry pioneers aimed at addressing the growing challenges in the dry eye market. With an increasing number of people affected by DED and the limitations of current treatments, the symposium will delve into the global state of dry eye care and the potential for future advancements. Topics will include the effects of technology on eye health, uncharted therapeutic options, and the acceleration of research and development to meet the urgent need for new clinical solutions.

OKYO Pharma is dedicated to developing innovative treatments for DED and neuropathic corneal pain (NCP), a painful ocular condition that currently lacks FDA-approved therapies. The company's shares are traded on the NASDAQ Capital Market, and it is actively pursuing the development of novel molecules to combat these conditions. Following the Phase 2 DED trial, OKYO is also preparing to initiate a Phase 2 trial for OK-101 to address NCP in patients suffering from this condition.